Acambis welcomes sanofi pasteur's dengue vaccine progress
The trial results were announced at a Research & Development meeting held in Paris, by sanofi-aventis. During the meeting, dengue fever was highlighted as one of the most common tropical diseases and a growing public health concern. Worldwide, 50-100 million people are affected and cases are appearing in northern Australia and Texas. Sanofi pasteur also highlighted that the potential market for a dengue vaccine could be worth in excess of EUR1bn per annum.
Sanofi pasteur also highlighted that it plans to start a large-scale Phase 3 efficacy study in 2008, making this project the first tetravalent candidate dengue vaccine in the world to reach this stage of clinical development.
Organizations
Related link
Other news from the department research and development
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.